Silexion Therapeutics (NASDAQ:SLXN) Shares Scheduled to Reverse Split on Wednesday, November 11th

Silexion Therapeutics Corp (NASDAQ:SLXN) shares are going to reverse split on the morning of Wednesday, November 11th. The 1-24 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, November 10th.

Silexion Therapeutics Price Performance

NASDAQ:SLXN traded down $0.01 during mid-day trading on Tuesday, reaching $0.11. 635,055 shares of the company’s stock traded hands, compared to its average volume of 3,242,905. The company has a 50 day moving average price of $0.25 and a 200-day moving average price of $6.16. The firm has a market capitalization of $605,484.00, a price-to-earnings ratio of -0.00 and a beta of -0.30. Silexion Therapeutics has a 12-month low of $0.11 and a 12-month high of $32.38.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Saturday, August 15th. The company reported ($5.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($21.20) by $16.03. As a group, analysts forecast that Silexion Therapeutics will post -4.70 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on SLXN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Friday, September 11th. Maxim Group downgraded Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is an Israel-based clinical-stage biotechnology company developing RNA-based medicines for the treatment of solid tumors driven by mutations in the KRAS oncogene. The company’s technology is designed to selectively silence cancer-causing KRAS mutations while limiting exposure to healthy tissue. Silexion’s lead program, siG12D-LODER, is an investigational RNA interference therapy targeting the KRAS G12D mutation, which is frequently found in pancreatic and other difficult-to-treat cancers.